🫁 ICS-LABA Controller vs Reliever Simulator

Airway at Rest — Chronic Inflammation Under the Surface

A resting asthmatic airway is never truly calm — inflammation simmers continuously.

• 15–20%: Baseline FEV1 reduction (in uncontrolled asthma)
• +50–200%: Smooth muscle mass (vs healthy airway)
• Elevated: Mucosal eosinophils (chronic Th2 inflammation)
• No effect: Reliever alone (on inflammation)

Chronic airway inflammation

Eosinophils and cytokines infiltrate the airway wall.

Smooth muscle hypertrophy

Bronchial muscle thickens and tightens the airway.

Mucosal edema

Swollen mucosa narrows the airway lumen further.

Reliever Mechanism — Beta-2 Agonism and Rapid Bronchodilation

Short-acting beta-2 agonists relax airway muscle within minutes, not weeks.

• 3–5 min: Onset of action (inhaled salbutamol)
• 15–30 min: Peak bronchodilation (post-dose)
• 4–6 hrs: Duration of effect (short-acting β2-agonist)
• 0%: Inflammation change (muscle-only action)

Beta-2 receptor binding

Salbutamol binds beta-2 receptors on airway smooth muscle.

cAMP-driven relaxation

cAMP rises, muscle relaxes, airway widens within minutes.

Symptom relief only

Bronchodilation eases symptoms but inflammation stays untouched.

Controller Mechanism — ICS Anti-Inflammatory Action Plus LABA

Inhaled corticosteroids work slowly, quieting the immune cascade over weeks.

• Days: ICS onset (measurable anti-inflammatory effect)
• 2–4 wks: Full ICS effect (daily adherence)
• 12 hrs: LABA duration (sustained bronchodilation)
• Up to 90%: Eosinophil reduction (with adherent ICS use)

ICS suppresses transcription

Corticosteroids switch off inflammatory gene expression.

Eosinophil and cytokine decline

Eosinophils, IL-4, IL-5, IL-13 fall over days to weeks.

LABA sustains bronchodilation

Formoterol or salmeterol keeps airways open for hours.

Combined Maintenance Therapy — Daily ICS-LABA Dosing

Regular combination dosing keeps baseline inflammation low, not just symptoms hidden.

• Up to 50%: Exacerbation reduction (vs SABA-only regimen)
• Daily: Recommended use (regardless of symptoms)
• Sustained: FEV1 improvement (over weeks-months)
• Steps 1–5: GINA preferred step (per 2023 guidelines)

Daily dosing lowers baseline

Regular ICS-LABA keeps resting inflammation consistently low.

Fewer exacerbations

Lower baseline inflammation means fewer severe flare-ups.

Single-inhaler strategy

Some regimens use one inhaler for both roles.

Reliever Overreliance — Masked Inflammation, Rising Risk

Frequent rescue puffs without a controller quietly let inflammation escalate.

• >3 canisters/yr: SABA overuse threshold (signals poor control)
• Higher: Death risk (with >1 canister/month)
• Worsens silently: Masked inflammation (without controller therapy)
• Significantly increased: Exacerbation risk (per GINA 2023)

Frequent SABA masks decline

Repeated reliever puffs hide progressively worsening inflammation.

Beta-receptor desensitization

Overused receptors respond less well to rescue puffs.

Rising exacerbation risk

Unaddressed inflammation raises risk of severe attacks.